Nafithromycin

India's Nafithromycin, a new Macrolide antibiotic, aims to combat antimicrobial resistance, particularly in treating Community-Acquired Bacterial Pneumonia. Developed with significant investment and clinical trials, it offers improved efficacy and shorter treatment times. The government supports AMR initiatives, including the National Action Plan on AMR, to enhance surveillance and public awareness.

Indian scientists developed Nafithromycin, an indigenous antibiotic targeting Community-Acquired Bacterial Pneumonia (CABP), crucial in combating antimicrobial resistance (AMR). Marketed as 'Miqnaf', it treats drug-resistant bacteria, particularly affecting vulnerable populations. Nafithromycin, 10 times more effective than current treatments, offers a three-day regimen, improving patient compliance and safety. Experts emphasize the need for rational antibiotic use to prevent resistance.

India developed Nafithromycin, its first indigenous Macrolide antibiotic, after 30 years of research, to combat antimicrobial resistance (AMR). Nafithromycin, marketed as 'Miqnaf,' targets Community-Acquired Bacterial Pneumonia (CABP) and is ten times more effective than current treatments, offering a three-day treatment regimen. The drug, developed with ₹500 crores, awaits final approval from the Central Drugs Standard Control Organization (CDSCO). India also combats AMR through surveillance, awareness, and international collaboration initiatives.

CEAT to acquire Camso's Off-Highway construction equipment bias tyre and tracks business from Michelin for $225 Mn. Kerala Industries Minister urges entrepreneurs to invest in the state. Indian Oil Corporation launches initiatives for prison inmates and children in correctional homes. Magicbricks facilitates over 400 home bookings in Bengaluru. Rubber Market rates announced by the Rubber Board.

Nafithromycin (Miqnaf) developed by Wockhardt with BIRAC support targets CABP, addressing 2M+ annual deaths. It combats AMR, offers 10x efficacy over azithromycin, broad-spectrum action, minimal side effects, and is the first in its class worldwide in 30 years. Extensive clinical trials and ₹500 crore investment underscore its reliability. Awaiting CDSCO approval, it promises 96.7% cure rate for drug-resistant pneumonia and will be integrated into Ayushman Bharat, tackling the AMR crisis globally.

India's new drugs aim to combat antibiotic-resistant superbugs, with Enmetazobactam and Zaynich showing promise. Antibiotic resistance caused 1.14 million deaths globally in 2021, with India facing significant challenges. Innovative drugs and better prescription practices are crucial to address this growing threat.

India launches Nafithromycin, its first indigenous antibiotic to combat drug-resistant infections, developed by BIRAC. This new antibiotic, targeting CABP, offers a three-day, once-daily treatment, significantly more effective than azithromycin, with 96.7% clinical cure rate.

India launches Nafithromycin, the first indigenous antibiotic for drug-resistant infections, developed by BIRAC. The drug, branded as 'Miqnaf,' treats drug-resistant community-acquired bacterial pneumonia (CABP) in adults and is set to be distributed by Wolkardt. Nafithromycin, a novel semi-synthetic macrolide antibiotic, offers a once-daily, three-day therapy, 10 times more efficacious and with 8 times higher lung exposure than azithromycin. Developed over 14 years with an investment of Rs 500 crores, it targets both typical and atypical bacteria, providing a solution to the growing issue of antimicrobial resistance (AMR).

Nafithromycin, developed over 14 years with Rs 500 crore investment, marks a milestone in combating antimicrobial resistance (AMR). India's potential to lead in tackling AMR is highlighted, with small companies stepping up as big pharma exits antibiotic development.